BRD2 and neoplasm: All grading systems attempt to quantify the degree of regression or the amount of residual tumor, and there is agreement that a quantitative characterization of tumor regression is necessary for the evaluation of the effectiveness of NAT, and may have further role in therapeutic decisions (e.g. alternative treatments if no regression is present).